Studying the Effects of Abemaciclib Combined with Standard Therapy Compared Standard Therapy Alone when Used by People Diagnosed with Breast Cancer

What we are studying

The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18 - 80

Eligibility Criteria

  • The participant must be randomized within 16 months from the time of surgery.

What is involved

  • Study participants will be randomized to receive abemaciclib plus standard adjuvant endocrine therapy versus standard endocrine therapy alone


Parking will be validated for all study related visits

Contact Information

Study Coordinator
Charity Patton

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.